ESPERION THERAPEUTICS INC
ESPRNASDAQTrading Snapshot
- Day Range
- $3.14 – $3.22
- 52-Week Range
- $1.62 – $4.18
- Volume
- $2.91B
- Avg Volume
- $3.63B
- Shares Outstanding
- 257.7M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $403M
- Last Q Revenue
- $80M
- P/E Ratio
- —
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-0.06
- Dividend Yield
- —
Why Investors Own ESPR
- ✓High-growth profile — revenue up -9.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ESPERION THERAPEUTICS INC
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
